Anti-Mouse CD71/TfR1 Antibody (8D3) is a rat-derived anti-mouse CD71/TfR1 IgG2a type antibody inhibitor. Anti-Mouse CD71/TfR1 Antibody (8D3) depletes of CD71+ erythroid cells but does not change percentages of Tregs in neonatal mice. Anti-Mouse CD71/TfR1 Antibody (8D3) enhances neonatal mice defence against infection [1] [2].
In Vivo, Anti-Mouse CD71/TfR1 Antibody (8D3) (150 μg, i.p., on days 5 and 6 after birth) enhances neonatal mice defence against infection[1]. Anti-Mouse CD71/TfR1 Antibody (8D3) (150 μg, i.p., on days 9 after birth) depletes of CD71+ erythroid cells but does not change percentages of Tregs in neonatal mice[2].
In Vitro, The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
References:
[1]. Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2020 Jan;109(1):74-103.
[2]. Elahi S, et al. Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. Nature. 2013 Dec 5;504(7478):158-62.
[3]. Shahbaz S, et al. CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β. PLoS Biol. 2018 Dec 14;16(12):e2006649.
In Vivo, Anti-Mouse CD71/TfR1 Antibody (8D3) (150 μg, i.p., on days 5 and 6 after birth) enhances neonatal mice defence against infection[1]. Anti-Mouse CD71/TfR1 Antibody (8D3) (150 μg, i.p., on days 9 after birth) depletes of CD71+ erythroid cells but does not change percentages of Tregs in neonatal mice[2].
In Vitro, The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
References:
[1]. Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2020 Jan;109(1):74-103.
[2]. Elahi S, et al. Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. Nature. 2013 Dec 5;504(7478):158-62.
[3]. Shahbaz S, et al. CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β. PLoS Biol. 2018 Dec 14;16(12):e2006649.